Quavonlimab

• CAT Number: I040374
• CAS Number: 2254059-25-9
• Purity: ≥95%

Quavonlimab (Cat No.: I040374) is an investigational humanized monoclonal antibody that targets cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), a key immune checkpoint receptor. By blocking CTLA-4, quavonlimab enhances T-cell activation and proliferation, boosting the immune system’s ability to recognize and attack tumors. It is being studied in combination with other immune checkpoint inhibitors, such as PD-1/PD-L1 blockers, for the treatment of advanced solid tumors. Quavonlimab aims to improve antitumor responses in cancers with immune-evasive characteristics.

Reference

[1]. Perets R, et al. Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer. Ann Oncol. 2021;32(3):395-403.
[Content Brief]